Blincyto is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat relapsed or refractory cases of B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children. Blincyto is also indicated in cases of B-cell precursor ALL in remission with minimal residual disease. Blincyto may be referred to by its drug name, blinatumomab.
Blincyto is a biologic drug, a genetically engineered protein, or antibody, that targets the CD19 protein on B cells. Blincyto is believed to work by inducing T cells to kill B cells.
How do I take it?
Blincyto is administered as an intravenous infusion on a schedule that varies by individual case.
Blincyto comes in the form of a single-dose vial.
The FDA-approved label for Blincyto lists common side effects including headache, fever, infusion reactions, low blood cell counts, and infections.
Rare but serious side effects listed for Blincyto can include pancreatitis, dangerous infections, and severe and life-threatening neurological symptoms such as seizures. Blincyto can also cause cytokine release syndrome (CRS), a potentially fatal inflammatory reaction with severe neurological symptoms such as hallucinations and tremors.
For more details about this treatment, visit:
Blincyto — Amgen
ALL: Relapsed and Refractory — Leukemia & Lymphoma Society